摘要
目的探讨曲美他嗪(TMZ)对慢性心力衰竭(CHF)患者血清C-反应蛋白(CRP)、白介素6(IL-6)水平及心功能的影响。方法CHF患者90例随机单盲分成治疗组和对照组,均给予内科常规抗心衰治疗。对照组加服培哚普利,初始剂量2mg,每日1次,逐渐加至靶剂量4mg,每日1次;治疗组在对照组的基础上接受曲美他嗪20mg/次,3次/d,疗程3个月。观察治疗前后两组患者的左室收缩末期容积(LESV)、左室舒张末期容积(LEDV)、左室射血分数(LVEF)的改变及血清CRP、IL-6水平的变化。结果治疗后两组心功能较治疗前有明显改善,治疗组临床总有效率为95.6%,较对照组(80.0%)显著提高(P<0.05);超声心动图显示治疗组LVEF、LESV及LEDV较对照组改善明显,差异有统计学意义(P<0.05);治疗组血清CRP、IL-6水平下降较对照组更明显,差异有统计学意义(P<0.05)。结论曲美他嗪能明显改善充血性心力衰竭患者的心功能,可能与降低血浆CRP、IL-6水平有关。
Objective To study the effect of trimetazidine on serum levels of C-reactive protein（CRP） and interleukin-6（IL-6） and cardiac function of chronic congestive heart failure（CHF）. Methods Ninety patients with CHF were randomly divided into experimental group and control group. All patients were given conventional medical treatment, perindopril was added to the control group,the initial dose of 2mg/d,gradually increased to target dose of 4mg/d;Besides Perindopril,trimetazidine was added to the experimental group, 20mg,tid. 3 months later the changes in the serum levels of CRP and IL-6 and cardiac function were observed. Results The cardiac function in two groups were significantly improved.The clinical total effective rate was 95.6% in the experimental group,higher than that in the control group（80.0%）, and the blood pressure was significantly improved in the two groups（P〈0.05）. After treatment,LVEF, LESV and LEDV of the treatment group showed significant improvement compared with control group（P〈0.05）, and the serum levels of CRP and IL-6 were significantly decreaed（P〈 0.05）. Conclusion Trimetazidine can change the cardiac function of CHF patients, which may be related to a decrease in the serum levels of CRP and IL-6.
出处
《中国现代医生》
2009年第24期19-20,23,共3页
China Modern Doctor
